DIABLO and cancer: Small molecules that mimic the IAP-binding motif of second mitochondrial activator of caspases (SMAC, also known as DIABLO), the endogenous IAP antagonist [7], [8], named SMAC mimetics, have recently been developed and are being tested in human clinical cancer trials.